Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia

키워드

참고문헌 (100)

1. Ji S, "Sarcopenia as the mobility phenotype of aging : clinical implications", J Bone Metab, 31, pp.1~12 (2024)[DOI]
2. Cruz-Jentoft AJ, "Sarcopenia : revised European consensus on definition and diagnosis", Age Ageing, 48, pp.16~31 (2019)[DOI]
3. Petermann-Rocha F, "Physical capability markers used to define sarcopenia and their association with cardiovascular and respiratory outcomes and all-cause mortality : a prospective study from UK Biobank", Maturitas, 138, pp.69~75 (2020)[DOI]
4. Lim HS, "Association of dietary variety status and sarcopenia in Korean elderly", J Bone Metab, 27, pp.143~149 (2020)[DOI]
5. Petermann-Rocha F, "Factors associated with sarcopenia : a cross-sectional analysis using UK Biobank", Maturitas, 133, pp.60~67 (2020)[DOI]
6. Ahmed GM, "Impact of calcium channel blockers and angiotensin receptor blockers on hematological parameters in type 2 diabetic patients", Naunyn Schmiedebergs Arch Pharmacol, 397, pp.1817~1828 (2024)[DOI]
7. Hadid KA, "Mechanisms and linkage of insulin signaling, resistance, and inflammation", Iraq J Pharm, 21, pp.1~8 (2024)[DOI]
8. Hadid KA, "Beyond blood sugar : exploring the anti-inflammatory frontier of antidiabetic medications to alleviate diabetic complications", Rom J Med Pract, 19, pp.92~99 (2024)[DOI]
9. Faselis C, "Microvascular complications of type 2 diabetes mellitus", Curr Vasc Pharmacol, 18, pp.117~124 (2020)[DOI]
10. Ahmed GM, "The diabetic-anemia nexus : Implications for clinical practice", Mil Med Sci Lett, 92, pp.1~11 (2023)[DOI]
11. Trujillo JM, "GLP-1 receptor agonists : a review of head-to-head clinical studies", Ther Adv Endocrinol Metab, 6, pp.19~28 (2015)[DOI]
12. Nauck MA, "The evolving story of incretins(GIP and GLP-1)in metabolic and cardiovascular disease : a pathophysiological update", Diabetes Obes Metab, 23(Suppl 3), pp.5~29 (2021)[DOI]
13. Chai S, "Cognitive protection of incretinbased therapies in patients with type 2 diabetes mellitus : a systematic review and meta-analysis based on clinical studies", J Diabetes Investig, 14, pp.864~873 (2023)[DOI]
14. Guo C, "Glucagon-like peptide 1improves insulin resistance in vitro through anti-inflammation of macrophages", Braz J Med Biol Res, 49, pp.e5826~ (2016)[DOI]
15. Sandoval D, "Brain GLP-1 and insulin sensitivity", Mol Cell Endocrinol, 418(Pt 1), pp.27~32 (2015)[DOI]
16. Yaribeygi H, "Antioxidative potentials of incretin-based medications : a review of molecular mechanisms", Oxid Med Cell Longev, 2021, pp.9959320~ (2021)[DOI]
17. Alfahad M, "Comparison of anti-oxidant activity of different brands of esomeprazole available in Iraqi pharmacies", Syst Rev Pharm, 11, pp.330~334 (2020)[DOI]
18. Bellanti F, "Aging:oxidative stress and dietary antioxidants" (2020), Elsevier Inc
19. Baek KW, "Rodent model of muscular atrophy for sarcopenia study", J Bone Metab, 27, pp.97~110 (2020)[DOI]
20. Léger B, "Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy", J Physiol, 576, pp.923~933 (2006)[DOI]
21. Handayaningsih AE, "Reactive oxygen species play an essential role in IGF-I signaling and IGF-I-induced myocyte hypertrophy in C2C12 myocytes", Endocrinology, 152, pp.912~921 (2011)[DOI]
22. Thomson DM, "Impaired overload-induced muscle growth is associated with diminished translational signalling in aged rat fast-twitch skeletal muscle", J Physiol, 574, pp.291~305 (2006)[DOI]
23. Yoshida T, "Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy", Cells, 9, pp.1970~ (2020)[DOI]
24. Sakellariou GK, "Studies of mitochondrial and nonmitochondrial sources implicate nicotinamide adenine dinucleotide phosphate oxidase(s)in the increased skeletal muscle superoxide generation that occurs during contractile activity", Antioxid Redox Signal, 18, pp.603~621 (2013)[DOI]
25. Kim MJ, "The link between mitochondrial dysfunction and sarcopenia : an update focusing on the role of pyruvate dehydrogenase kinase 4", Diabetes Metab J, 47, pp.153~163 (2023)[DOI]
26. Yeo D, "Intensified mitophagy in skeletal muscle with aging is downregulated by PGC-1alpha overexpression in vivo", Free Radic Biol Med, 130, pp.361~368 (2019)[DOI]
27. Chabi B, "Mitochondrial function and apoptotic susceptibility in aging skeletal muscle", Aging Cell, 7, pp.2~12 (2008)[DOI]
28. Marzetti E, "Age-related activation of mitochondrial caspase-independent apoptotic signaling in rat gastrocnemius muscle", Mech Ageing Dev, 129, pp.542~549 (2008)[DOI]
29. St-Pierre J, "Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators", Cell, 127, pp.397~408 (2006)[DOI]
30. Alassaf FA, "Effects of bee propolis on fbg, hba1c, and insulin resistance in healthy volunteers", Turk J Pharm Sci, 18, pp.405~409 (2021)[DOI]
31. Liu ZJ, "Causal relationship between insulin resistance and sarcopenia", Diabetol Metab Syndr, 15, pp.46~ (2023)[DOI]
32. White JP, "Amino acid trafficking and skeletal muscle protein synthesis : a case of supply and demand", Front Cell Dev Biol, 9, pp.656604~ (2021)[DOI]
33. Ibrahim SL, "Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel", Br J Cancer, 128, pp.896~906 (2023)[DOI]
34. Long YC, "Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways", Mol Cell Biol, 31, pp.430~441 (2011)[DOI]
35. Vanhaesebroeck B, "PI3K signalling : the path to discovery and understanding", Nat Rev Mol Cell Biol, 13, pp.195~203 (2012)[DOI]
36. Lee MK, "Protective effect of pyropia yezoensis peptide on dexamethasone-induced myotube atrophy in C2C12 myotubes", Mar Drugs, 17, pp.284~ (2019)[DOI]
37. Timmerman KL, "Pharmacological vasodilation improves insulin-stimulated muscle protein anabolism but not glucose utilization in older adults", Diabetes, 59, pp.2764~2771 (2010)[DOI]
38. Cleasby ME, "Insulin resistance and sarcopenia : mechanistic links between common comorbidities", J Endocrinol, 229, pp.R67~R81 (2016)[DOI]
39. Ebert SM, "Stress-induced skeletal muscle Gadd45a expression reprograms myonuclei and causes muscle atrophy", J Biol Chem, 287, pp.27290~27301 (2012)[DOI]
40. Santos BF, "FOXO family isoforms", Cell Death Dis, 14, pp.702~ (2023)[DOI]
41. Mankhong S, "Experimental models of sarcopenia : bridging molecular mechanism and therapeutic strategy", Cells, 9, pp.1385~ (2020)[DOI]
42. Adeva-Andany MM, "The effects of glucagon and the target of rapamycin(TOR)on skeletal muscle protein synthesis and age-dependent sarcopenia in humans", Clin Nutr ESPEN, 44, pp.15~25 (2021)[DOI]
43. Ramasubbu K, "Impairment of insulin signaling pathway PI3K", Akt, Mol Cell Biochem, pp.2023, 478[DOI]
44. Hurrle S, "The etiology of oxidative stress in insulin resistance", Biomed J, 40, pp.257~262 (2017)[DOI]
45. Abed MN, "Comparison of antioxidant effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole", Pharmacology, 105, pp.645~651 (2020)[DOI]
46. Yaribeygi H, "Insulin resistance : review of the underlying molecular mechanisms", J Cell Physiol, 234, pp.8152~8161 (2019)[DOI]
47. Yaribeygi H, "A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress", J Cell Physiol, 234, pp.1300~1312 (2019)[DOI]
48. Yaribeygi H, "Antioxidative potential of antidiabetic agents : a possible protective mechanism against vascular complications in diabetic patients", J Cell Physiol, 234, pp.2436~2446 (2019)[DOI]
49. Khamseh ME, "Sarcopenia and diabetes : pathogenesis and consequences", Br J Diabetes Vasc Dis, 11, pp.230~234 (2011)[DOI]
50. Mesinovic J, "Sarcopenia and type 2 diabetes mellitus : a bidirectional relationship", Diabetes Metab Syndr Obes, 12, pp.1057~1072 (2019)[DOI]
51. Purnamasari D, "Sarcopenia and chronic complications of type 2 diabetes mellitus", Rev Diabet Stud, 18, pp.157~165 (2022)[DOI]
52. Tack W, "Pathophysiological interactions between sarcopenia and type 2 diabetes : a two-way street influencing diagnosis and therapeutic options", Diabetes Obes Metab, 26, pp.407~416 (2024)[DOI]
53. Bernardini F, "Incretins-based therapies and their cardiovascular effects : new game-changers for the management of patients with diabetes and cardiovascular disease", Pharmaceutics, 15, pp.1858~ (2023)[DOI]
54. Kobayashi M, "The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds", Mol Cell Biol, 29, pp.493~502 (2009)[DOI]
55. Civantos E, "Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a", Keap-1, Diabetes Metab Syndr Obes, pp.2017, 10[DOI]
56. Li Q, "GLP-1 inhibits high-glucose-induced oxidative injury of vascular endothelial cells", Sci Rep, 7, pp.8008~ (2017)[DOI]
57. Shiraki A, "Glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation", J Am Coll Cardiol, 59, pp.E904~ (2012)[DOI]
58. Deng C, "Liraglutide activates the Nrf2", HO-1antioxidant pathway and protects brain nerve cells against cerebral ischemia in diabetic rats, 2018, pp.2018, 3094504~
59. Alsalim W, "Effect of singledose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects", Diabetes Obes Metab, 20, pp.1080~1085 (2018)[DOI]
60. Armstrong MJ, "Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis", J Hepatol, 64, pp.399~408 (2016)[DOI]
61. Jasim MHM, "Synthesis, characterization, ADME study and in-vitro anti-inflammatory activity of aspirin amino acid conjugates", Pharm Chem J, 57, pp.243~249 (2023)[DOI]
62. Thomas MK, "Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes", J Clin Endocrinol Metab, 106, pp.388~396 (2021)[DOI]
63. Meloni AR, "GLP-1 receptor activated insulin secretion from pancreatic β-cells : mechanism and glucose dependence", Diabetes Obes Metab, 15, pp.15~27 (2013)[DOI]
64. Lee YS, "Anti-inflammatory effects of GLP-1-based therapies beyond glucose control", Mediators Inflamm, 2016, pp.3094642~ (2016)[DOI]
65. Giannocco G, "Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats", Eur J Pharmacol, 698, pp.74~86 (2013)[DOI]
66. Silva Júnior WS, "Dipeptidyl peptidase 4 activity is related to body composition, measures of adiposity, and insulin resistance in subjects with excessive adiposity and different degrees of glucose tolerance", J Diabetes Res, 2019, pp.5238013~ (2019)[DOI]
67. Kim MH, "EX4 stabilizes and activates Nrf2 via PKCδ, contributing to the prevention of oxidative stress-induced pancreatic beta cell damage", Toxicol Appl Pharmacol, 315, pp.60~69 (2017)[DOI]
68. Kawamori D, "GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice", Diabetologia, 60, pp.1442~1453 (2017)[DOI]
69. Shimoda M, "The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes", Diabetologia, 54, pp.1098~1108 (2011)[DOI]
70. Tomas E, "GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes", Regul Pept, 167, pp.177~184 (2011)[DOI]
71. Puddu A, "An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes", Mediators Inflamm, 2013, pp.591056~ (2013)[DOI]
72. Patel V, "Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1diabetic mice", Pharmacol Rep, 65, pp.927~936 (2013)[DOI]
73. Okada K, "Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus", Endocrine, 47, pp.962~964 (2014)[DOI]
74. Rizzo M, "Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes : a prospective pilot study", J Clin Endocrinol Metab, 100, pp.603~606 (2015)[DOI]
75. Fernández-Millán E, "Glucagonlike peptide-1 improves beta-cell antioxidant capacity via extracellular regulated kinases pathway and Nrf2 translocation", Free Radic Biol Med, 95, pp.16~26 (2016)[DOI]
76. Oh YS, "Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling", Int J Mol Sci, 19, pp.26~ (2017)[DOI]
77. Cardoso JFR, "Perspectives of incretin mimetics in cardiovascular diseases", Braz J Health Biomed Sci, 20, pp.55~62 (2021)[DOI]
78. Girges C, "The future of incretin-based approaches for neurodegenerative diseases in older adults: which to choose? A review of their potential efficacy and suitability", Drugs Aging, 38, pp.355~373 (2021)[DOI]
79. Kalaitzoglou E, "Diabetes pharmacotherapy and effects on the musculoskeletal system", Diabetes Metab Res Rev, 35, pp.e3100~ (2019)[DOI]
80. Gilbert MP, "GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy : review of head-to-head clinical trials", Front Endocrinol(Lausanne), 11, pp.178~ (2020)[DOI]
81. Yaribeygi H, "Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity", Life Sci, 234, pp.116776~ (2019)[DOI]
82. Duan K, "The clinical relevance and mechanism of skeletal muscle wasting", Clin Nutr, 40, pp.27~37 (2021)[DOI]
83. Cetrone M, "Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II", Curr Diabetes Rev, 10, pp.231~237 (2014)[DOI]
84. Alnaser RI, "Adulteration of hypoglycemic products : the silent threat", Rom J Med Pract, 18, pp.202~205 (2023)[DOI]
85. Al-Dabbagh BMA, "Antiinflammatory, antioxidant and hepatoprotective potential of milk thistle in albino rats", Lat Am J Pharm, 41, pp.1832~1841 (2022)
86. Andreozzi F, "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", J Transl Med, 14, pp.229~ (2016)[DOI]
87. Colin IM, "Extrapancreatic effects of incretin hormones : evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat(ZFR)", Physiol Rep, 4, pp.e12886~ (2016)[DOI]
88. Takada S, "Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling", Cardiovasc Res, 111, pp.338~347 (2016)[DOI]
89. Perna S, "Liraglutide and obesity in elderly : efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study", Aging Clin Exp Res, 28, pp.1251~1257 (2016)[DOI]
90. Liu J, "Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes", J Diabetes Complications, 30, pp.1555~1559 (2016)[DOI]
91. Yajima T, "The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis", J Diabetes Complications, 32, pp.759~763 (2018)[DOI]
92. Friedrichsen M, "The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity", Diabetes Obes Metab, 23, pp.754~762 (2021)[DOI]
93. Ard J, "Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists", Adv Ther, 38, pp.2821~2839 (2021)[DOI]
94. Moore PW, "GLP-1 agonists for weight loss : pharmacology and clinical implications", Adv Ther, 40, pp.723~742 (2023)[DOI]
95. McLeod M, "Live strong and prosper : the importance of skeletal muscle strength for healthy ageing", Biogerontology, 17, pp.497~510 (2016)[DOI]
96. Cohen S, "Muscle wasting in disease : molecular mechanisms and promising therapies", Nat Rev Drug Discov, 14, pp.58~74 (2015)[DOI]
97. Locatelli JC, "Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?", Diabetes Care, pp.dci230100~ (2024)[DOI]
98. Hartono FA, "The effects of dietary protein supplementation on acute changes in muscle protein synthesis and longer-term changes in muscle mass, strength, and aerobic capacity in response to concurrent resistance and endurance exercise in healthy adults : a systematic review", Sports Med, 52, pp.1295~1328 (2022)[DOI]
99. Hoffman MD, "Proper hydration during ultra-endurance activities", Sports Med Arthrosc Rev, 27, pp.8~14 (2019)[DOI]
100. Bellicha A, "Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity : an overview of 12 systematic reviews and 149 studies", Obes Rev, 22(Suppl 4), pp.e13256~ (2021)[DOI]

관련 논문AI추천